IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-04-17
DOI
10.3389/fimmu.2021.678999
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multi-omics integration analysis robustly predicts high-grade patient survival and identifies CPT1B effect on fatty acid metabolism in Bladder Cancer
- (2019) Venkatrao Vantaku et al. CLINICAL CANCER RESEARCH
- A Prospective Targeted Serum Metabolomics Study of Pancreatic Cancer in Postmenopausal Women
- (2019) Li Jiao et al. Cancer Prevention Research
- Multiplexing protein and gene level measurements on a single Luminex platform
- (2019) Damon B. Cook et al. METHODS
- Ovarian cancer: time to move beyond one size fits all
- (2019) Angeles Alvarez Secord LANCET ONCOLOGY
- Ovarian cancer statistics, 2018
- (2018) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tumor-Repopulating Cells Induce PD-1 Expression in CD8 + T Cells by Transferring Kynurenine and AhR Activation
- (2018) Yuying Liu et al. CANCER CELL
- IDO decreases glycolysis and glutaminolysis by activating GCN2K, while it increases fatty acid oxidation by activating AhR, thus preserving CD4+ T‑cell survival and proliferation
- (2018) Theodoros Eleftheriadis et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- IDO takes a blow
- (2018) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Inhibition of the aryl hydrocarbon receptor/polyamine biosynthesis axis suppresses multiple myeloma
- (2018) Anna Bianchi-Smiraglia et al. JOURNAL OF CLINICAL INVESTIGATION
- Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond
- (2018) Alexander J. Muller et al. Seminars in Immunopathology
- A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer
- (2017) Rebecca Kristeleit et al. GYNECOLOGIC ONCOLOGY
- Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
- (2017) et al. JAMA Oncology
- AHR Function in Lymphocytes: Emerging Concepts
- (2016) Liang Zhou TRENDS IN IMMUNOLOGY
- The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
- (2016) Vinit Kumar et al. TRENDS IN IMMUNOLOGY
- LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
- (2015) Ruea-Yea Huang et al. Oncotarget
- NAD+ protects against EAE by regulating CD4+ T-cell differentiation
- (2014) Stefan G. Tullius et al. Nature Communications
- Current Approaches and Challenges in Managing and Monitoring Treatment Response in Ovarian Cancer
- (2014) Charlotte S Marcus et al. Journal of Cancer
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position
- (2013) Jason D Buenrostro et al. NATURE METHODS
- Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation
- (2012) Feng Qian et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Monocytic CCR2+ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor Microenvironment
- (2011) A. M. Lesokhin et al. CANCER RESEARCH
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
- (2011) Christiane A. Opitz et al. NATURE
- Quinolinate phosphoribosyl transferase, a key enzyme in de novo NAD+ synthesis, suppresses spontaneous cell death by inhibiting overproduction of active-caspase-3
- (2010) Kazumi Ishidoh et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- MetPA: a web-based metabolomics tool for pathway analysis and visualization
- (2010) J. Xia et al. BIOINFORMATICS
- Longitudinal, Noninvasive Imaging of T-Cell Effector Function and Proliferation in Living Subjects
- (2010) M. R. Patel et al. CANCER RESEARCH
- An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
- (2010) J. D. Mezrich et al. JOURNAL OF IMMUNOLOGY
- Antigen-Specific Immunity and Cross-Priming by Epithelial Ovarian Carcinoma-Induced CD11b+Gr-1+ Cells
- (2010) K. Tomihara et al. JOURNAL OF IMMUNOLOGY
- Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell–like and Foxp3+ regulatory T cells
- (2010) Roopali Gandhi et al. NATURE IMMUNOLOGY
- Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
- (2010) Junko Matsuzaki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CH223191 Is a Ligand-Selective Antagonist of the Ah (Dioxin) Receptor
- (2010) Bin Zhao et al. TOXICOLOGICAL SCIENCES
- Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase–Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer
- (2009) Feng Qian et al. CANCER RESEARCH
- Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma
- (2009) Tomoko Inaba et al. GYNECOLOGIC ONCOLOGY
- Evidence for Ligand-Mediated Selective Modulation of Aryl Hydrocarbon Receptor Activity
- (2009) I. A. Murray et al. MOLECULAR PHARMACOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started